Researcher
Erwin Dreesen
- Disciplines:Biomarker evaluation, Biopharmaceutics, Pharmacodynamics, Pharmacokinetics, Pharmacotherapy, Computational biomodelling and machine learning
Affiliations
- Department of Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Oct 2021 → 30 Sep 2022 - Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Oct 2019 → Today - Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Sep 2014 → 30 Sep 2019
Projects
1 - 10 of 15
- Handling of social determinants in pharmacokinetics-pharmacodynamics analyses to enhance equity and inclusion in drug dosing in neonates, children, and adolescentsFrom4 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Model informed Dosage optimization of Crizanlizumab for the management of Sickle Cell Disease in TanzaniaFrom17 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Joint pharmacometrics modeling of antimicrobial exposure, biomarkers, and clinical outcome assessments to improve the in silico exploration of dose optimization strategies in critically ill patientsFrom28 Aug 2023 → TodayFunding: FWO Strategic Basic Research Grant
- STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: STRADA-CEF trial.From1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Model-informed precision dosing of tacrolimus in solid organ transplant recipientsFrom27 Jul 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Pharmacodynamics models to bridge the gap between exposure and response to antimicrobial treatmentsFrom1 Oct 2021 → 30 Sep 2023Funding: BOF - projects
- Antibacterial dose optimisation based on augmented renal clearance in adult critically ill patients and selected pediatric patientsFrom1 Oct 2021 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Master protocol methodological pharmacometrics researchFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Gastrointestinal physiology and drug disposition in geriatric patientsFrom5 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Beyond optimising drug exposure: Pharmacodynamic models to bridge the gap between exposure and response to antimicrobial treatmentsFrom15 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
11 - 20 of 97
- A personalised taper-to-target strategy with adalimumab in Crohn's disease(2023)
Authors: Erwin Dreesen, Bram Verstockt
Pages: 293 - 294 - A MATHEMATICAL MODEL FOR SELECTING REGIMEN COMPOSITION AND DURATION BASED ON PHENOTYPE FOR PATIENTS WITH DRUG-SUSCEPTIBLE TUBERCULOSIS(2023)
Authors: Erwin Dreesen
Pages: S52 - S52 - Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review(2023)
Authors: Nada Dia, Erwin Dreesen, Thomas Vanassche, Peter Verhamme, Lorenz Van der Linden, Jos Tournoy
Pages: 351 - 373 - A MATHEMATICAL MODEL FOR SELECTING REGIMEN COMPOSITION AND DURATION BASED ON PHENOTYPE FOR PATIENTS WITH DRUG--SUSCEPTIBLE TUBERCULOSIS(2023)
Authors: Erwin Dreesen
Pages: S46 - S46 - THERAPEUTIC DRUG MONITORING CAN GUIDE THE INTRAVENOUS-TO -SUBCUTANEOUS SWITCH OF INFLIXIMAB AND VEDOLIZUMAB: A PHARMACOKINETIC SIMULATION STUDY(2023)
Authors: Marc Ferrante, Erwin Dreesen
Pages: S48 - S49 - Model-informed precision dosing of infliximab to improve outcomes of individual patients with inflammatory bowel diseases(2023)
Authors: Wannee Kantasiripitak, Erwin Dreesen, Marc Ferrante, Debby Thomas
- Liposomal amphotericin B exposure in critically ill patients: a prospective pharmacokinetic study(2022)
Authors: Ruth Van Daele, Joost Wauters, Omar Elkayal, Erwin Dreesen, Yves Debaveye, Katrien Lagrou, Johan Maertens
- Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia(2022)
Authors: Erwin Dreesen, Matthias Gijsen, Omar Elkayal, Pieter Annaert, Yves Debaveye, Joost Wauters
Pages: 2479 - 2488 - Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies(2022)
Authors: Liselotte Fierens, Erwin Dreesen, João Guedelha Sabino, Marc Ferrante
Pages: 1059 - 1069 - Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases(2022)
Authors: Wannee Kantasiripitak, Alex Kensert, Zhigang Wang, João Guedelha Sabino, Séverine Vermeire, Debby Thomas, Marc Ferrante, Erwin Dreesen
Pages: 1045 - 1059